IL2RB and neoplasm: Remarkably, the “Triplet” therapy combining Ad-p53 with selective CD122/CD132 agonists and immune checkpoint blockade resulted in the complete tumor remissions and potentially curative outcomes that significantly surpassed the efficacy of all other doublet and monotherapies tested none of which resulted in complete responses nor extended survivals.